You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

refractory ascite

Showing 1 - 25 of 8,818
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ascites, Paracentesis, Cirrhosis Trial in France (Alphapump, Ascites puncture)

Recruiting
  • Ascites
  • +2 more
  • Alphapump
  • Ascites puncture
  • Amiens, France
  • +8 more
Jun 9, 2022

Refractory Pain Trial in Spain

Recruiting
  • Refractory Pain
    • Málaga, Andalucia, Spain
    • +4 more
    Aug 1, 2023

    Dermatitis Herpetiformis Trial in Tampere (Assessment of prognosis of refractory dermatitis herpetiformis. No intervention)

    Enrolling by invitation
    • Dermatitis Herpetiformis
    • Assessment of prognosis of refractory dermatitis herpetiformis. No intervention
    • Tampere, Finland
      Tampere University Hospital
    Aug 18, 2023

    Pib Specific Phage, Intractable Constipation Trial in Shanghai (phage)

    Recruiting
    • Pib Specific Phage
    • Intractable Constipation
    • phage
    • Shanghai, China
      Shanghai Tenth People's Hospital
    Jul 25, 2023

    Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal

    Completed
    • Colorectal Cancer
    • Fruquintinib combined with anti-PD-1 antibodies
    • ChangSha, Hunan, China
      Hunan Cancer Hospital
    Aug 27, 2023

    Intravitreal Dexamethasone Implant for Refractory Diabetic

    Completed
    • Diabetic Macular Edema
    • Intravitreal Dexamethasone Implant for refractory Diabetic macular edema:
    • Cairo, Egypt
      Kasr alainy faculty of medicine
    May 5, 2023

    Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission Trial in São Paulo (Bortezomib)

    Not yet recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • Acute Lymphoblastic Leukemia With Failed Remission
    • São Paulo, SP, Brazil
      Instituto do Cancer do Estado de Sao Paulo
    Sep 12, 2023

    Colon Cancer Trial in Qingdao (Chimeric antigen receptor T cell preparation targeting GCC)

    Recruiting
    • Colon Cancer
    • Chimeric antigen receptor T cell preparation targeting GCC
    • Qingdao, Shandong, China
      The Affiliated Hospital of Qingdao University
    May 16, 2023

    MDS Trial (Roxadustat in combination with retinoic acid)

    Not yet recruiting
    • Myelodysplastic Syndromes
    • Roxadustat in combination with retinoic acid
    • (no location specified)
    Aug 26, 2023

    AML, Adult Recurrent, MDS Trial in United States (LYT-200)

    Recruiting
    • AML, Adult Recurrent
    • MDS
    • Los Angeles, California
    • +13 more
    Apr 12, 2023

    Advanced Solid Tumor, Stereotactic Body Radiotherapy, Immune Checkpoint Inhibitor Trial in Peking (Cadonilimab, Stereotactic

    Not yet recruiting
    • Advanced Solid Tumor
    • +4 more
    • Peking, Beijing, China
      Department of radiation oncology, Peking University Third Hospit
    Jun 20, 2023

    Axial Spondyloarthritis Trial in Dhaka (Baricitinib 2mg, Tofacitinib 5 mg)

    Recruiting
    • Axial Spondyloarthritis
    • Baricitinib 2mg
    • Tofacitinib 5 mg
    • Dhaka, Bangladesh
      Bangabandhu Sheikh Mujib Medical University
    Nov 1, 2023

    Multiple Myeloma, Refractory, Multiple Myeloma in Relapse Trial in Cleveland (Autologous CAR-T cell therapy expressing the

    Not yet recruiting
    • Multiple Myeloma, Refractory
    • Multiple Myeloma in Relapse
    • Autologous CAR-T cell therapy expressing the BAFF-ligand.
    • Cleveland, Ohio
      University Hospitals Seidman Cancer Center
    Jan 11, 2023

    Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Marginal Zone Lymphoma Trial in France (Atezolizumab, Obinutuzumab,

    Completed
    • Follicular Lymphoma
    • +3 more
    • Angers, France
    • +24 more
    Jan 9, 2023

    Steroid-refractory Acute Graft-versus-Host Disease, Treatment-refractory Acute Graft-versus-Host Disease Trial in United States

    Completed
    • Steroid-refractory Acute Graft-versus-Host Disease
    • Treatment-refractory Acute Graft-versus-Host Disease
    • Neihulizumab (ALTB-168)
    • Duarte, California
    • +12 more
    Jan 17, 2023

    Corneal Toxicity in Patients Treated by Belantamab Mafodotin

    Completed
    • Myeloma Multiple
    • Collection of datas
    • Dijon, France
    • +9 more
    May 31, 2023

    Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

    Completed
    • Metastatic Colorectal Adenocarcinoma
    • regorafenib plus anti-PD-1 antibodies
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Jul 4, 2023

    Brain Gliomas Trial in Suzhou (Allogenic B7H3 CAR-?dT cell)

    Recruiting
    • Brain Gliomas
    • Allogenic B7H3 CAR-γδT cell
    • Suzhou, Jiangsu, China
      Dushu Lake Hospital Affiliated to Soochow University
    Aug 25, 2023

    Marginal Zone Lymphoma Trial in Tianjin (Obinutuzumab, lenalidomide)

    Recruiting
    • Marginal Zone Lymphoma
    • Obinutuzumab, lenalidomide
    • Tianjin, Tian, China
      Institute of Hematology & Blood Diseases Hospital
    Apr 27, 2023

    Peripheral T Cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

    Recruiting
    • Peripheral T Cell Lymphoma
    • Linperlisib in combined with Chidamide
    • Beijing, Beijing/China, China
    • +1 more
    Oct 9, 2023

    Non-hodgkin's Lymphoma Trial in Beijing (GNC-035)

    Not yet recruiting
    • Non-hodgkin's Lymphoma
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Sep 27, 2023

    Neuroblastoma Trial (GD2 CAR T cells)

    Not yet recruiting
    • Neuroblastoma
    • GD2 CAR T cells
    • (no location specified)
    Aug 5, 2023

    T-lymphoblastic Lymphoma, T-ALL Trial in Shanghai (CAR-T)

    Recruiting
    • T-lymphoblastic Lymphoma
    • T-ALL
    • CAR-T
    • Shanghai, China
      Shanghai Ruijin Hospital
    Nov 14, 2023

    AML, Adult Trial (Pharmacoscopy, Clinical standard-of-care (physician's choice))

    Not yet recruiting
    • AML, Adult
    • Pharmacoscopy
    • Clinical standard-of-care (physician's choice)
    • (no location specified)
    Nov 20, 2023

    Mantle Cell Lymphoma Trial in China (400mg of TQB3909 tablets, 600mg of TQB3909 tablets)

    Recruiting
    • Mantle Cell Lymphoma
    • 400mg of TQB3909 tablets
    • 600mg of TQB3909 tablets
    • Beijing, Beijing, China
    • +27 more
    Oct 26, 2023